# Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.

Source: https://onco.cc/trials/nct07518329/  
OnCo record `nct07518329` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of ALA-101 run by Arovella Therapeutics Ltd, now recruiting.

## Summary

Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia. is a phase 1 interventional study registered as NCT07518329 by Arovella Therapeutics Ltd, with 46 participants planned, started 2026-10-19. Conditions recorded: Non Hodgkin Lymphoma (NHL) and Leukaemia. Interventions recorded: ALA-101.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07518329
- Phase: 1
- Setting: A Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101, Allogeneic, Off-the-shelf, CD19-directed CAR-iNKT Cells in Patients With CD19+ Non-Hodgkin Lymphoma and Leukemia
- Sponsor: Arovella Therapeutics Ltd
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT07518329: https://clinicaltrials.gov/study/NCT07518329

## Connected records

- cancers: [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [ALA-101](https://onco.cc/drugs/ala-101/)
- companies: [Arovella Therapeutics](https://onco.cc/companies/arovella-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07518329.json